(0.08%) 5 521.50 points
(0.12%) 39 891 points
(0.19%) 19 789 points
(0.00%) $81.63
(0.43%) $2.82
(-0.30%) $2 337.40
(0.02%) $29.53
(0.36%) $1 005.40
(0.01%) $0.931
(0.00%) $10.53
(-0.01%) $0.788
(-0.85%) $87.25
-0.32% $ 6.19
Live Chart Being Loaded With Signals
La Jolla Pharmaceutical Company engages in the development and commercialization of therapies that improve outcomes in patients suffering from life-threatening diseases...
Stats | |
---|---|
Dzisiejszy wolumen | 960 928 |
Średni wolumen | 0 |
Kapitalizacja rynkowa | 0.00 |
EPS | $0.0766 ( Q2 | 2022-08-15 ) |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E |
47.62 (Sector) 42.63 (Industry) 24.32 |
ATR14 | $0.137 (2.20%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2022-08-22 | Rosen Robert | Sell | 30 000 | Stock Option (Right to Buy) |
2022-08-22 | Rosen Robert | Sell | 18 000 | Stock Option (Right to Buy) |
2022-08-22 | Rosen Robert | Sell | 10 000 | Stock Option (Right to Buy) |
2022-08-22 | Rosen Robert | Sell | 10 000 | Stock Option (Right to Buy) |
2022-08-22 | Rosen Robert | Sell | 10 000 | Stock Option (Right to Buy) |
INSIDER POWER |
---|
-100.00 |
Last 100 transactions |
Buy: 0 | Sell: 11 680 911 |
Wolumen Korelacja
La Jolla Pharmaceutical Korelacja
10 Najbardziej pozytywne korelacje |
---|
10 Najbardziej negatywne korelacje |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
La Jolla Pharmaceutical Korelacja - Waluta/Towar
La Jolla Pharmaceutical Finanse
Annual | 2021 |
Przychody: | $75.72M |
Zysk brutto: | $62.23M (82.19 %) |
EPS: | $0.720 |
FY | 2021 |
Przychody: | $75.72M |
Zysk brutto: | $62.23M (82.19 %) |
EPS: | $0.720 |
FY | 2020 |
Przychody: | $33.42M |
Zysk brutto: | $25.60M (76.60 %) |
EPS: | $-1.440 |
FY | 2019 |
Przychody: | $23.05M |
Zysk brutto: | $20.66M (89.62 %) |
EPS: | $-4.30 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
La Jolla Pharmaceutical
La Jolla Pharmaceutical Company engages in the development and commercialization of therapies that improve outcomes in patients suffering from life-threatening diseases. The company offers GIAPREZA, a vasoconstrictor indicated to increase blood pressure in adults with septic or other distributive shock; and XERAVA, a tetracycline class antibacterial indicated for the treatment of complicated intra-abdominal infections in patients 18 years of age and older. It offers GIAPREZA and XERAVA to hospitals and other healthcare organizations in the United States. Its product candidates that are in early stage clinical or preclinical development include TP-6076, an IV formulation of a fully synthetic fluorocycline derivative for the treatment of certain multidrug-resistant gram-negative bacteria; TP-271, an IV and oral formulation of a fully synthetic fluorocycline for the treatment of respiratory disease caused by bacterial biothreat and antibiotic-resistant public health pathogens, as well as bacterial pathogens associated with community-acquired bacterial pneumonia; and TP-2846, an IV formulation of a tetracycline for the treatment of acute myeloid leukemia. The company has license agreement with Everest Medicines Limited to develop and commercialize XERAVA; and PAION AG to commercialize GIAPREZA and XERAVA. La Jolla Pharmaceutical Company was incorporated in 1989 and is based in Waltham, Massachusetts. As of August 22, 2022, La Jolla Pharmaceutical Company operates as a subsidiary of Innoviva, Inc.
O Sygnały na żywo
Prezentowane na tej stronie sygnały na żywo pomagają określić, kiedy KUPIĆ lub SPRZEDAĆ BRAK DANYCH. Sygnały mogą mieć opóźnienie wynoszące nawet 1 minutę; jak wszystkie sygnały rynkowe, istnieje ryzyko błędu lub pomyłki.
Sygnały transakcyjne na żywo nie są ostateczne i getagraph.com nie ponosi odpowiedzialności za żadne działania podjęte na podstawie tych sygnałów, jak opisano w Warunkach Użytkowania. Sygnały opierają się na szerokim zakresie wskaźników analizy technicznej